Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET

TARRYTOWN, N.Y., Feb. 9, 2011 /PRNewswire/ — Regeneron
Pharmaceuticals, Inc. (Nasdaq:
REGN) today announced that it will webcast an investor briefing
on Sunday, February 13 from 9 a.m. to 10:30 a.m. Eastern Time.
 At the investor briefing, principal investigators from the
VEGF Trap-Eye clinical studies will recap presentations from the
Bascom Palmer Eye Institute’s Angiogenesis, Exudation and
Degeneration 2011 meeting being held in Miami, Florida on Saturday,
February 12.  

The investigator presentations will provide additional data from
the VIEW 1 and VIEW 2 Phase 3 trials in patients with the
neovascular form of age-related macular degeneration (wet AMD), the
COPERNICUS Phase 3 trial in macular edema due to central retinal
vein occlusion (CRVO), and the DA VINCI Phase 2 trial in diabetic
macular edema (DME).  Regeneron reported positive top-line
results from all these trials in the fourth quarter of 2010.

“It’s a privilege to be able to release this important
collection of VEGF Trap-Eye data at the Bascom Palmer Eye
Institute’s Eighth Annual Angiogenesis Meeting,” said  Philip
J. Rosenfeld, M.D., Ph.D., Professor of Ophthalmology, University
of Miami Miller School of Medicine and Course Co-Director of the
Angiogenesis 2011 Meeting.  “In particular, the Phase 3
results in wet AMD suggest that the VEGF Trap-Eye has the potential
to address an important unmet need of providing optimal vision gain
while reducing the burden of intravitreal injections and office
visits for patients and their caregivers.”  

The webcast and slides may be accessed through the Company’s web
site, www.regeneron.com, on the
Investor Relations page (http://investor.regeneron.com).
 An archived version of the presentation will be available
after the live webcast through M

‘/>”/>

SOURCE